Skip to main content
HCA
NYSE Industrial Applications And Services

HCA Healthcare Beats Q1 EPS Estimates, Reaffirms Guidance, and Repurchases $1.57B in Shares

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare Facility Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$437
Mkt Cap
$105.978B
52W Low
$321.39
52W High
$556.52
52W Position info
36% above low
Off High info
21% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

HCA sits 36% above its 52-week low of $321.39.

Summary

HCA Healthcare announced Q1 2026 results, beating EPS estimates, reaffirming its full-year guidance, and executing a substantial $1.57 billion share repurchase.


Key Events · Earnings and Guidance · HCA

  • Q1 Earnings Beat Expectations

    HCA Healthcare reported diluted earnings per share of $7.15 for Q1 2026, surpassing analyst estimates of $7.00. Revenues increased 4.3% to $19.109 billion compared to the prior year.

  • Full-Year Guidance Reaffirmed

    The company reaffirmed its previously issued 2026 estimated guidance ranges, maintaining its outlook for the full year despite a dynamic operating environment.

  • Significant Share Repurchases

    During the first quarter of 2026, HCA Healthcare repurchased 3.157 million shares of its common stock at a cost of $1.571 billion, with $9.179 billion remaining under its authorization as of March 31, 2026.

  • Quarterly Dividend Declared

    The Board of Directors declared a quarterly cash dividend of $0.78 per share, payable on June 30, 2026, to stockholders of record on June 16, 2026.


Analysis · HCA · Industrial Applications And Services

HCA Healthcare reported first-quarter earnings that surpassed analyst expectations, demonstrating solid financial performance despite some operational headwinds. The company's diluted EPS of $7.15 exceeded estimates, and revenues also saw a healthy increase. The reaffirmation of its full-year 2026 guidance, originally issued on January 27, 2026, provides stability and confidence in its outlook. Furthermore, the significant repurchase of $1.571 billion in common stock during the quarter underscores the company's commitment to returning capital to shareholders and reflects strong cash flow generation. This substantial capital return, representing a notable portion of its market capitalization, is a strong positive signal.

At the time of this filing, HCA was trading at $437.00 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $106B. The 52-week trading range was $321.39 to $556.52. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HCA - Latest Insights

HCA
Jul 24, 2026, 8:13 AM EDT
Source: dpa-AFX
Importance Score:
7
Price at Filing: $379.20
Real-time Price: $377.42 info
Change: -$1.78 (-0.47%) info
Market Cap: $84.785B info
HCA
Jul 24, 2026, 7:57 AM EDT
Source: dpa-AFX
Importance Score:
8
Price at Filing: $369.00
Real-time Price: $377.42 info
Change: +$8.42 (+2%) info
Market Cap: $84.785B info
HCA
Jul 24, 2026, 7:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $369.00
Real-time Price: $377.42 info
Change: +$8.42 (+2%) info
Market Cap: $84.785B info
HCA
Jul 24, 2026, 7:43 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $369.00
Real-time Price: $377.42 info
Change: +$8.42 (+2%) info
Market Cap: $84.785B info
HCA
Jul 20, 2026, 7:21 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $385.55
Real-time Price: $377.42 info
Change: -$8.13 (-2%) info
Market Cap: $84.785B info